A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis Barry J Plant, Damian G Downey, Joe.

Slides:

Advertisements

Similar presentations

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Advertisements

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

Dorene F. Balmer, Joan I. Schall, Virginia A. Stallings

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

The immediate effect of musculoskeletal physiotherapy techniques and massage on pain and ease of breathing in adults with cystic fibrosis Annemarie Lee,

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients Karen.

William G. Flight, Jonathan Shaw, Susan Johnson, A

K. L. Nash, M. E. Allison, D. McKeon, D. J. Lomas, C. S. Haworth, D

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.

The ease of breathing test tracks clinical changes in cystic fibrosis

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Inhaled aztreonam lysine vs

Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function William R. Hunt, Beth R. Helfman,

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

Molecular detection of an atypical, highly resistant, clonal Pseudomonas aeruginosa isolate in cystic fibrosis patients Deirdre Keating, Mary J. Crowe,

The Journal of Cystic Fibrosis: Sunny perspectives

Treatment response of airway clearance assessed by single-breath washout in children with cystic fibrosis Chiara Abbas, Florian Singer, Sophie Yammine,

Asians with cystic fibrosis in the UK have worse disease outcomes than clinic matched white homozygous ΔF508 controls Jonathan McCormick, Simon A. Ogston,

An evaluation strategy for potential QTc prolongation with chronic azithromycin therapy in cystic fibrosis Patrick John Lenehan, Craig M. Schramm, Melanie.

A.H. Gifford Journal of Cystic Fibrosis

Treatment of resistant distal intestinal obstruction syndrome with a modified antegrade continence enema procedure I.J. Clifton, A.M. Morton, N.S. Ambrose,

Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis Elizabeth F. Shead, Charles S. Haworth,

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Cystic fibrosis related diabetes in an extremely young patient

Physiologic endpoints for clinical studies for cystic fibrosis

Association between practice patterns and body mass index percentile in infants and young children with cystic fibrosis Raj Padman, Lloyd N. Werk, Gabriela.

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Saliva cyclic GMP increases during anaesthesia

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR function Kavitha Kotha, Rhonda D. Szczesniak,

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

Lung clearance index during hospital admission in school-age children with cystic fibrosis Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai,

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Newsome S.J. , Daniel R.M. , Carr S.B. , Bilton D. , Keogh R.H.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry Sanja Stanojevic, Janet Stocks,

Gautham Marigowda, Fang Liu, David Waltz Journal of Cystic Fibrosis

Voriconazole therapy in children with cystic fibrosis

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines Kathleen J. Ramos, Patrick J. Smith, Edward.

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa C.E. Wainwright, A.L. Quittner, D.E.

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Cystic fibrosis and pregnancy in the modern era: A case control study

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

H. White, A.M. Morton, D.G. Peckham, S.P. Conway

Presentation transcript:

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis Barry J Plant, Damian G Downey, Joe A Eustace, Cedric Gunaratnam, Charles S Haworth, Andrew M Jones, Edward F McKone, Daniel G Peckham, R. Ian Ketchell, Diana Bilton Journal of Cystic Fibrosis Volume 16, Issue 6, Pages 695-701 (November 2017) DOI: 10.1016/j.jcf.2017.02.006 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Boxplots showing median within-patient change (solid line), interquartile range (box) and outlying (circle) and extreme outlying (asterisks) values for: (A) FEV1% predicted between 6 and 12months (P2) and 0–6months pre- (P1) initiation of inhaled aztreonam lysine therapy (on left) and between 0 and 6months pre- (P1) and 0–6months post- (T1) initiation of therapy (on right); (B) FEV1% predicted in all patients across the four time periods. p-Values calculated using Wilcoxon Signed Rank tests. Journal of Cystic Fibrosis 2017 16, 695-701DOI: (10.1016/j.jcf.2017.02.006) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Boxplot showing median (solid line) and interquartile range (box) and outlying values for body mass index (BMI) across consecutive 6-month periods using all available data. p-Values calculated using Wilcoxon Signed Rank test. Journal of Cystic Fibrosis 2017 16, 695-701DOI: (10.1016/j.jcf.2017.02.006) Copyright © 2017 The Authors Terms and Conditions